Show simple item record

dc.contributor.authorJuan-Giner, Aen
dc.contributor.authorTchaton, Men
dc.contributor.authorJemmy, JPen
dc.contributor.authorSoumah, Aen
dc.contributor.authorBoum, Yen
dc.contributor.authorFaga, EMen
dc.contributor.authorCisse, Men
dc.contributor.authorGrais, RFen
dc.date.accessioned2018-10-16T16:42:37Z
dc.date.available2018-10-16T16:42:37Z
dc.date.issued2018-09-25
dc.date.submitted2018-10-04
dc.identifier.citationSafety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. 2018 Vaccineen
dc.identifier.issn1873-2518
dc.identifier.pmid30266489
dc.identifier.doi10.1016/j.vaccine.2018.09.009
dc.identifier.urihttp://hdl.handle.net/10144/619279
dc.description.abstractAs part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP. Here we summarize the information on the safety follow-up.
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/journal/0264410Xen
dc.rightsPublished by Elsevier Archived on this site with kind permission and copyright 200X from Elsevieren
dc.titleSafety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guineaen
dc.identifier.journalVaccineen
refterms.dateFOA2019-03-04T14:10:23Z
html.description.abstractAs part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP. Here we summarize the information on the safety follow-up.


Files in this item

Thumbnail
Name:
Juan-Giner et al - 2018 - Safety ...
Size:
699.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record